<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>capecitabine &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/capecitabine/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 07 Oct 2026 13:37:37 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>capecitabine &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Oral Drug S-1 Linked to Longer Survival Than Capecitabine in Metastatic Breast Cancer Study</title>
		<link>https://bioengineer.org/oral-drug-s-1-linked-to-longer-survival-than-capecitabine-in-metastatic-breast-cancer-study/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 07 Oct 2026 13:37:37 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[capecitabine]]></category>
		<category><![CDATA[CDK4/6 inhibitors]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[fluoropyrimidine]]></category>
		<category><![CDATA[HER2-negative]]></category>
		<category><![CDATA[hormone receptor-positive]]></category>
		<category><![CDATA[Metastatic Breast Cancer]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[progression-free survival]]></category>
		<category><![CDATA[retrospective cohort study]]></category>
		<category><![CDATA[S-1]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=405871</guid>

					<description><![CDATA[A retrospective cohort study of 123 patients suggests the oral fluoropyrimidine S-1 may deliver longer overall survival than capecitabine as first-line chemotherapy for hormone receptor-positive, HER2-negative metastatic breast cancer, with prior CDK4/6 inhibitor exposure leaving outcomes largely unchanged.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">405871</post-id>	</item>
	</channel>
</rss>
